Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients

1. A method for the in-vitro diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency without any discomforts (NYHA stage I), wherein a determination of the marker proANP or NT-proANP, or fragments or partial peptides thereof is carried out parallel to a determination of the marker proBNP, NT-proBNP, and/or BNP on patients to be examined.

2. The method for the in-vitro diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency without any discomforts (NYHA stage I) of claim 1 , wherein the marker is MR-proANP (AS 53-90 of NT-proANP).

3. The method for the in-vitro diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency without any discomforts (NYHA stage I) of claim 1 , wherein the patient has a body mass index of at least 30 kg/m 2 .

4. The method for the in-vitro diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency without any discomforts (NYHA stage I), of claim 1 , for making clinical decisions and for the hospitalization of patients.

5. The method for the in-vitro diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency without any discomforts (NYHA stage I), of claim 1 , for the differential diagnostic early detection and detection, assessment of severity, and for therapy accompanying assessment of course.

6. The method of claim 1 , wherein a determination of at least one further marker, selected from the group consisting of inflammatory markers, cardiovascular markers, and ischemic markers, is additionally carried out on a patient to be examined.

7. The method of claim 6 , wherein the inflammatory marker is selected from the group consisting of C-reactive protein (CRP), cytokines, interleukins, procalcitonin (1-116, 3-116), and adhesion molecules.

8. The method of claim 6 , wherein the cardiovascular marker is selected from the group consisting of creatine kinesis, myeloperoxidasis, copeptin, myoglobin, cardiac troponin, CRP, and circulation regulating (pro)hormones.

9. The method of claim 6 , wherein the ischemic marker is selected from the group consisting of troponin I, troponin T and CK-MB.

10. The method of claim 1 , wherein parallel or simultaneous determinations of the markers are carried out.

11. The method of claim 10 , wherein the determinations are carried out on at least one patient sample.

12. The method claim 10 , wherein the determinations are carried out on an automatic analyzer.

13. The method claim 10 , wherein the determinations are carried out by means of a rapid test.

14. The method of claim 4 , wherein the clinical decisions relate to continuative treatment and therapy by means of medication, or intensive medicine or emergency medicine.

15. The method of claim 7 , wherein the inflammatory marker is selected from the group consisting of TNF-alpha, IL-6, VCAM and ICAM.

16. The method of claim 8 , wherein the cardiovascular marker is a circulation regulating (pro)hormone selected from the group consisting of pro-gastrin releasing peptide (proGRP), pro-endothelin (proEnd), pro-leptin, pro-neuropeptide-Y, pro-somatostatin, pro-neuropeptide-YY, pro-opiomelanocortin, pro-adrenomedullin (proADM), copeptine, and a partial sequence thereof.